Optinose is a specialty pharmaceutical company focused on the development and commercialization of products for patients cared for by, or in consultation with, ear, nose, and throat (ENT) or allergy specialists. We are focused on value creation, starting with our work on a unique and novel drug delivery concept known as Bi-Directional™ Exhalation Delivery Systems. The innovative mechanism of action of the first Optinose technology is designed to enable broad, consistent drug delivery high and deep in the nasal passages, leveraging the mucosal surfaces as a potential target for the treatment of both local and systemic diseases. These Bi-Directional™ Exhalation Delivery Systems (EDS) offer a much-needed alternative to traditional nasal sprays, as well as nasal nebulizers, tablets, and injections. We market XHANCE™, a corticosteroid indicated for the treatment of nasal polyps in patients 18 years of age or older. Optinose has offices in the U.S., the U.K. and Norway. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.